Biomea Fusion is trading at $1.31, up 5.20% during the October 7 session, with no clear company-specific catalyst identified.

  • Biomea Fusion’s latest listed press release was September 23, announcing termination of a proposed public offering.
  • Biotech and major indexes are down, so broader market trends do not explain the stock’s gain.